Mokari Atabak, Chief Financial Officer of Corcept Therapeutics Inc. (NASDAQ:CORT), executed a sale of 40,000 shares on June 1, 2026, valued at $2.8 million. This transaction, conducted under a pre-arranged 10b5-1 trading plan initiated on December 12, 2025, saw the shares sold at prices between $70.00 and $70.01. Following the sale, Corcept's stock has risen to $72.68, marking a 9% increase over the past week and a 109% gain year-to-date. Despite the sale, Atabak also acquired additional shares through a purchase plan, indicating continued investment in the company. Corcept recently reported first-quarter revenues of approximately $164.9 million, a 4.9% increase from the previous year, and raised its full-year revenue guidance to between $950 million and $1.05 billion. The company is optimistic following positive results from the Phase 3 ROSELLA trial for its drug Lifyorli, which demonstrated a 35% reduction in the risk of death for patients with platinum-resistant ovarian cancer. H.C. Wainwright has responded positively, raising its price target for Corcept shares to $75.